Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro

International Journal of Radiation Biology

Volumn 90, Issue 8, 2014, Pages 678-686

  Eke, Iris ^a,b   Ingargiola, Mirjam ^a   Förster, Claudia ^a   Kunz Schughart, Leoni A ^a   Baumann, Michael ^a,b,d   Runge, Roswitha ^a   Freudenberg, Robert ^a   Kotzerke, Jörg ^a   Heldt, Jan Martin ^c   Pietzsch, Hans Jürgen ^c   Steinbach, Jörg ^c   Cordes, Nils ^a,b,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Department of Radiation Oncology ^*  (United States)

^c Institute of Radiopharmaceutical Cancer Research   (United States)

^d INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

Cetuximab; EGFR; Radionuclide; Targeted radioimmunotherapy

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE H2AX; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PENTETIC ACID; PROTEIN KINASE B; YTTRIUM 90;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLONOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DOSIMETRY; DOUBLE STRANDED DNA BREAK; DRUG CONJUGATION; ENZYME PHOSPHORYLATION; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIOACTIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION;

CETUXIMAB; EGFR; RADIONUCLIDE; TARGETED RADIOIMMUNOTHERAPY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL COUNT; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DNA BREAKS, DOUBLE-STRANDED; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; INTRACELLULAR SPACE; MOLECULAR TARGETED THERAPY; PENTETIC ACID; PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; YTTRIUM RADIOISOTOPES;

EID: 84905387838     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2014.899446     Document Type: Article

References (30)

1. Avram AM. 2012. Radioiodine scintigraphy with SPECT/CT: An important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med 53: 754-764.
2. Bentzen SM, Trotti A. 2007. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25: 4096-4103.
3. Berger C, Madshus IH, Stang E. 2012. Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis. Exp Cell Res 318: 2578-2591.
4. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, et al. 2006. Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578.
5. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, et al. 2010. Radiotherapy plus Cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between Cetuximab-induced rash and survival. Lancet Oncol 11: 21-28.
6. Brunner TB, Kunz-Schughart LA, Grosse-Gehling P, Baumann M. 2012. Cancer stem cells as a predictive factor in radiotherapy. Semin Radiat Oncol 22: 151-174.
7. Chopra A. 2004. 111 In/ 86 Y-Labeled F(ab )2 fragment of panitumumab, a fully human monoclonal antibody directed against the extracellular domain III of the epidermal growth factor receptor. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda, MD: National Center for Biotechnology Information (US).
8. Eke I, Cordes N. 2011. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures. Radiother Oncol 99: 279-286.
9. Eke I, Sandfort V, Storch K, Baumann M, Roper B, Cordes N. 2007. Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro. Int J Radiat Biol 83: 793-802.
10. Eke I, Storch K, Krause M, Cordes N. 2013a. Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis. Cancer Res 73: 5869-5879.
11. Eke I, Schneider L, Forster C, Zips D, Kunz-Schughart LA, Cordes N. 2013b. EGFR/JIP-4/JNK2 signaling attenuates Cetuximab-mediated radiosensitization of squamous cell carcinoma cells. Cancer Res 73: 297-306.
12. Fraunholz I, Rödel F, Kohler D, Diallo-Georgiopoulou M, Distel L, Falk S, Rödel C. 2013. Epidermal growth factor receptor expression as prognostic marker in patients with anal carcinoma treated with concurrent chemoradiation therapy. Int J Radiat Oncol Biol Phys 86: 901-907.
13. Freudenberg R, Wendisch M, Kotzerke J. 2011. Geant4-simulations for cellular dosimetry in nuclear medicine. Z Med Phys 21: 281-289.
14. Gurtner K, Deuse Y, Butof R, Schaal K, Eicheler W, Oertel R, Grenman R, et al. 2011. Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiother Oncol 99: 323-330.
15. Huhtala T, Laakkonen P, Sallinen H, Yla-Herttuala S, Narvanen A. 2010. In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111 In-labeled monoclonal antibodies. Nucl Med Biol 37: 957-964.
16. Ingargiola M, Dittfeld C, Runge R, Zenker M, Heldt JM, Steinbach J, Cordes N, et al. 2012. Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation. Cytometry A 81: 865-873.
17. Leung K. 2004. 86 Y-CHX-A ? -diethylenetriamine pentaacetic acidpanitumumab. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda, MD: National Center for Biotechnology Information (US) [updated 2011 Dec 2008].
18. Mazzeo E, Hehlgans S, Valentini V, Baumann M, Cordes N. 2012. The impact of cell-cell contact, E-cadherin and EGF receptor on the cellular radiosensitivity of A431 cancer cells. Radiat Res 178: 224-233.
19. Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW. 2008. Cetuximab: Preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 23: 619-631.
20. Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, et al. 2010. PET imaging of HER1-expressing xenografts in mice with 86 Y-CHX-A ? -DTPA-Cetuximab. Eur J Nucl Med Mol Imaging 37: 1368-1376.
21. Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW. 2011. HER1-targeted 86 Y-panitumumab possesses superior targeting characteristics than 86 Y-Cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS One 6: e18198.
22. Palanichamy K, Chakravarti A. 2009. Combining drugs and radiotherapy: From the bench to the bedside. Curr Opin Neurol 22: 625-632.
23. Rades D, Wolff C, Nadrowitz R, Breunig C, Schild SE, Baehre M, Meller B. 2009. Radioactive EGFR antibody Cetuximab in multimodal cancer treatment: Stability and synergistic effects with radiotherapy. Int J Radiat Oncol Biol Phys 75: 1226-1231.
24. Rodemann HP, Dittmann K, Toulany M. 2007. Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 83: 781-791.
25. Saker J, Kriegs M, Zenker M, Heldt JM, Eke I, Pietzsch HJ, Grenman R, et al. 2013. Inactivation of HNSCC cells by 90 Y-labeled Cetuximab strictly depends on the number of induced DNA double-strand breaks. J Nucl Med 54: 416-423.
26. Saki M, Toulany M, Sihver W, Zenker M, Heldt JM, Mosch B, Pietzsch HJ, et al. 2012. Cellular and molecular properties of ( 90 ) Y-labeled Cetuximab in combination with radiotherapy on human tumor cells in vitro. Strahlenther Onkol 188: 823-832.
27. Storch K, Eke I, Borgmann K, Krause M, Richter C, Becker K, Schrock E, et al. 2010. Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res 70: 3925-3934.
28. Wei Q, Shui Y, Zheng S, Wester K, Nordgren H, Nygren P, Glimelius B, et al. 2011. EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. Oncol Rep 25: 3-11.
29. Wen X, Wu QP, Ke S, Ellis L, Charnsangavej C, Delpassand AS, Wallace S, et al. 2001. Conjugation with ( 111 )In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. J Nucl Med 42: 1530-1537.
30. Zips D, Krause M, Yaromina A, Dorfler A, Eicheler W, Schutze C, Gurtner K, et al. 2008. Epidermal growth factor receptor inhibitors for radiotherapy: Biological rationale and preclinical results. J Pharm Pharmacol 60: 1019-1028.